Skip to main content
Neuropsychopharmacology logoLink to Neuropsychopharmacology
. 2016 Aug 11;41(10):2624. doi: 10.1038/npp.2016.78

A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies

Anke Post, Trevor S Smart, Judith Krikke-Workel, Gerard R Dawson, Catherine J Harmer, Michael Browning, Kimberley Jackson, Rishi Kakar, Richard Mohs, Michael Statnick, Keith Wafford, Andrew McCarthy, Vanessa Barth, Jeffrey M Witkin
PMCID: PMC4987860  PMID: 31265521

Correction to: Neuropsychopharmacology (2016) 41, 1803–1812; doi:10.1038/npp.2015.348; published online 16 December 2015

In this Article, page 1804, right column, the ‘Evaluation of an Antidepressant Effect' section should be read as follows:

Evaluation of an Antidepressant Effect

Forced-swim test is a behavioral despair test, which predicts the efficacy of antidepressant treatments, and was used as described by Witkin et al (2014). Immobility time was analyzed with a one-way ANOVA followed by Dunnett's test.

Correspondingly, in the references, the Gleason et al (2015) reference should be replaced with the following reference:

Witkin JM, Overshiner C, Li X, Catlow JT, Schober DA, Heinz BA, Nikolayev A, Tolstikov VV, Anderson WH, Higgs RE, Kuo M-S, Felder CC (2014). The M1 and M2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly-acting antidepressant scopolamine. J Pharmacol Exp Ther 351: 448-456.


Articles from Neuropsychopharmacology are provided here courtesy of Nature Publishing Group

RESOURCES